ArticleNeurotoxicity research2025
Streptozotocin and L-Buthionine-Sulfoximine Decrease Neuron Membrane Lipid Packing and Alter Insulin Signaling.
Article in Neurotoxicity research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Membrane composition, permeability and fluidity are essential for proper cellular function. According to the membrane aging hypothesis, aging-related diseases, including neurodegenerative disorders, arise from the aging of cell membranes. Membrane proteins, such as the insulin receptor, rely on an optimal membrane environment for proper partitioning and functionality. Our goal was to investigate the effects of streptozotocin (STZ) and L-buthionine-sulfoximine (BSO), two commonly used agents to model aging and neurodegeneration, on membrane composition and permeability, as well as their impact on insulin signaling. Mouse neuroblastoma 2a cell line (neuro-2a) were treated with STZ (6 h) and BSO (24 h). Cell viability was assessed by the MTT assay. Cholesterol and sphingomyelin content were quantified by commercial kits, while membrane polarity was evaluated with the Laurdan probe. Gene expression of Srebf2 and Cyp46a1 was analyzed by qPCR. Proteins from the insulin signaling pathway were examined by immunoblotting. STZ treatment reduced neuronal cholesterol content, downregulated Srebf2 and Cyp46a1 gene expression, and decreased membrane packing. In contrast, BSO-treated cells exhibited increased sphingomyelin content, upregulated Srebf2 and Cyp46a1 gene expression, and decreased membrane packing. Both treatments induced an insulin-resistant state, which we attribute to alterations in the membrane environment.
Indexed as
Identifiers
40439741What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.